TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

M D Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.